[ANTH] Anthera Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 131.58 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.97 Change: 0.06 (3.14%)
Ext. hours: Change: 0 (0%)

chart ANTH

Refresh chart

Strongest Trends Summary For ANTH

ANTH is in the long-term down -100% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing products to treat diseases associated with inflammation and autoimmune diseases. It is developing blisibimod, a Phase III product candidate that targets elevated levels of B-cell activating factor associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy, lupus nephritis, multiple myeloma, vasculitis, idiopathic thrombocytopenia purpura, and others. The company was founded in 2004 and is headquartered in Hayward, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding40.99 M EPS-12.51 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-0.15
P/E To EPS Growth P/S P/BV3.75 Price/Cash Per Share
Price/Free Cash Flow ROA-67.36% ROE-83.58% ROI
Current Ratio6.17 Quick Ratio Long Term Debt/Equity Debt Ratio0.2
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities45.63 M Cash From Investing Activities-10 K Cash From Operating Activities-6.61 M Gross Profit
Net Profit-7.66 M Operating Profit-7.66 M Total Assets43.57 M Total Current Assets43.16 M
Total Current Liabilities6.99 M Total Debt Total Liabilities8.46 M Total Revenue240 K
Technical Data
High 52 week3.28 Low 52 week0.31 Last close0.32 Last change-1.64%
RSI49.62 Average true range0.02 Beta1.3 Volume515.23 K
Simple moving average 20 days-4.42% Simple moving average 50 days-68.47% Simple moving average 200 days-77.83%
Performance Data
Performance Week-7.04% Performance Month-3.5% Performance Quart-83.14% Performance Half-78.58%
Performance Year-89.57% Performance Year-to-date-80.79% Volatility daily3.59% Volatility weekly8.03%
Volatility monthly16.46% Volatility yearly57.01% Relative Volume61.67% Average Volume2.93 M
New High New Low

News

2018-12-10 14:31:46 | Last-minute tips for health coverage before Dec. 15 deadline

2018-08-31 07:40:00 | Report: Developing Opportunities within Anthera Pharmaceuticals, NRG Energy, Antares Pharma, El Pollo Loco, Paychex, and Cinedigm — Future Expectations, Projections Moving into 2018

2018-06-29 07:10:00 | Anthera Pharma and Three Additional Stocks Under Scanner in the Biotech Space

2018-06-28 08:26:54 | Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut

2018-06-27 15:12:40 | Anthera Pharma Stock Plunged 53% Today, ANTH Suspended Tomorrow

2018-06-27 08:00:00 | Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the NASDAQ Capital Markets

2018-06-04 14:42:21 | What You Must Know About Anthera Pharmaceuticals Inc’s NASDAQ:ANTH Market Risks

2018-05-24 16:11:22 | Breaking Down Anthera Pharmaceuticals Inc’s NASDAQ:ANTH Ownership Structure

2018-05-23 07:00:00 | Free Daily Technical Summary Reports on Amicus Therapeutics and Three Other Biotech Stocks

2018-05-08 11:39:14 | What Do Analysts Think About Anthera Pharmaceuticals Inc’s NASDAQ:ANTH Long Term Outlook?

2018-05-04 08:20:00 | New Research: Key Drivers of Growth for Global Medical REIT, DXP Enterprises, SJW, FTI Consulting, Anthera Pharmaceuticals, and Alexandria Real Estate Equities — Factors of Influence, Major Initiatives and Sustained Production

2018-04-10 10:07:16 | Breakeven On The Horizon For Anthera Pharmaceuticals Inc NASDAQ:ANTH

2018-03-23 08:48:28 | Did Anthera Pharmaceuticals Inc’s NASDAQ:ANTH Recent Earnings Growth Beat The Trend?

2018-03-19 07:30:00 | Research Report Identifies Anthera Pharmaceuticals, Hancock Holding, MKS Instruments, Second Sight Medical Products, Eclipse Resources, and Aircastle with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2018-03-12 17:55:07 | East Bay company's stock plummets 81% as drug for cystic fibrosis patients fails

2018-03-12 17:38:05 | East Bay company's stock plummets 81% as drug for cystic fibrosis patients fails

2018-03-12 08:47:47 | Anthera Pharmaceuticals' stock plunges toward record low after failed drug trial

2018-03-12 08:00:00 | Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura

2018-03-07 08:30:00 | Anthera Pharmaceuticals to Present at the 30TH Annual ROTH Conference

2018-03-06 14:45:00 | Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing Criteria

2018-03-05 16:05:00 | Anthera Pharmaceuticals Provides Business Update and Reports 2017 Fourth Quarter and Fiscal Year Financial Results

2018-03-05 11:02:20 | Best Growth Stock Picks

2018-02-26 09:00:02 | Implied Volatility Surging for Anthera Pharmaceuticals ANTH Stock Options

2018-02-08 08:30:00 | Anthera Pharmaceuticals to Participate in the BIO CEO & Investor Conference and SunTrust Robinson Humphrey’s 4th Annual Orphan Drug Day

2018-02-05 08:30:00 | Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of Sollpura

2018-01-31 10:34:03 | Will Bristol-Myers' BMY Q4 Earnings Exceed Expectations?

2018-01-30 08:26:01 | What's in Store for Cardinal Health CAH in Q2 Earnings?

2018-01-25 16:30:00 | Anthera Receives Positive Nasdaq Listing Determination

2018-01-25 08:10:00 | Today’s Research Reports on Trending Tickers: Anthera Pharmaceuticals and Cara Therapeutics

2018-01-24 07:02:12 | The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ

2018-01-23 10:45:03 | Anthera's Sollpura Strong on Positive Futility in Phase III

2018-01-23 08:57:01 | Fancy Biotech Stocks on Buyout Buzz? 5 Top Picks

2018-01-22 08:30:00 | Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura: Study On Schedule for Topline Data this Quarter

2018-01-17 08:10:00 | Report: Exploring Fundamental Drivers Behind Anthera Pharmaceuticals, Alarm, Aptevo Therapeutics, Shoe Carnival, Independent Bank, and First Internet — New Horizons, Emerging Trends, and Upcoming Developments

2018-01-09 17:15:00 | Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering

2018-01-08 17:54:10 | Ultragenyx Announces Interim Data from Early Stage Study

2018-01-08 08:30:00 | Anthera Pharmaceuticals Announces Results of Special Meeting of Stockholders

2018-01-03 08:30:00 | Anthera Pharmaceuticals Announces Appointment of Patrick Murphy as Senior Vice President, Manufacturing

2017-12-11 08:30:00 | Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura

2017-11-29 15:37:09 | Want To Invest In Anthera Pharmaceuticals Inc ANTH? Here’s How It Performed Lately

2017-11-25 11:02:22 | Best Growth Stocks To Buy

2017-11-17 16:05:00 | Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal

2017-11-09 08:30:00 | Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura

2017-11-06 11:52:09 | Who Are The Major Shareholders Of Anthera Pharmaceuticals Inc ANTH?

2017-11-06 08:43:21 | Anthera reports 3Q loss

2017-11-06 08:30:00 | Anthera Pharmaceuticals Provides Business Update and Reports 2017 Third Quarter Financial Results

2017-11-05 08:30:00 | Anthera Pharmaceuticals Announces Presentation of Blisibimod Data at the American College of Rheumatology Annual Meeting

2017-11-02 08:30:00 | Anthera Pharmaceuticals Announces Presentations of Sollpura Data at the North American Cystic Fibrosis Conference

2017-11-01 17:00:00 | Anthera Pharmaceuticals Announces Presentation of Blisibimod Lupus Research at the American Society of Nephrology Annual Meeting

2017-10-24 08:30:00 | Anthera Pharmaceuticals Announces Pricing of $15 Million Private Placement Offering